Medtronic (NYSE:MDT) said today that it’s launching a study in the U.S. and Japan to evaluate dual antiplatelet therapy in high bleeding risk patients implanted with the Resolute Onyx drug-eluting stent during percutaneous coronary intervention.
The company’s Onyx One Clear study is one of the first designed to assess the risk of cardiac death and stent thrombosis following DAPT interruption or discontinuation after one month with a next-gen drug-eluting stent, according to Medtronic.
Get the full story at our sister site, Drug Delivery Business News.
The post Medtronic launches one-month DAPT study for drug-eluting stent in U.S., Japan appeared first on MassDevice.
from MassDevice https://ift.tt/2QjhrL9
Cap comentari:
Publica un comentari a l'entrada